Effect of Smoking on Ventilation-Perfusion Ratio

Status Recruiting

Clinical Trial Summary

Smoking is one of the world's leading health hazards. Besides being a major risk factor in the etiology of COPD and lung cancer, cigarette smoke is also a causative agent lung diseases characterized by bronchiolar and interstitial inflammation. However, the associated lung pathology of smoking is not only a risk in the development of lung diseases, but also widely recognized as a major risk factor associated with perioperative respiratory and cardiovascular complications. Apart from the long term effects of cigarette smoke, acute effects of the inhalation of cigarettes smoke may influence the course of lung pathology. The inhalation of smoke causes inflammation in the lung by inducing chemotaxis and activation of neutrophils and macrophages and induces oxidative stress. As the acute inflammatory response to smoke inhalation seems to be the underlying mechanism for chronic diseases of smokers, exploring the field of the acute pulmonary changes after exposure to cigarette smoke is highly relevant. One reason for acute hypoxia and injury during smoking might be a severe mismatch of ventilation and perfusion of the lung. Using the multiple inert gas elimination technique (MIGET), a distribution of ventilation-perfusion ratios in the lung can be calculated by analyzing data on the retention and excretion of six infused inert gases. A saline solution containing the gases is infused intravenously. When passing through the lung the gases are either eliminated from the blood or retained depending on their partition coefficient and local V/Q ratio. The concentrations of the gases are measured in the mixed venous blood or the mixed expired gas and the arterial blood allowing for the calculation of retention and excretion and the derivation of V/Q distribution. MIGET is the experimental gold standard to determine the Ventilation-Perfusion ratio of the lung. The aim of this study is to show the acute effect of smoking on ventilation/perfusion ratio distribution in the lung in otherwise healthy smokers.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT02963467
Study type	Interventional
Source	Medical University of Vienna
Contact	Stefan Boehme, Ass.-Prof. Dr.
Phone	00436766767144
Email	stefan.boehme@meduniwien.ac.at
Status	Recruiting
Phase	N/A
Start date	September 17, 2018
Completion date	September 2019

View Details

See also
Status	Clinical Trial	Phase
Withdrawn	`NCT02253667` - Palliative Use of High-flow Oxygen Nasal Cannula in End-of-life Lung Disease Patients	N/A
Completed	`NCT02217423` - Abdominal Circumference and Cardiorespiratory Repercussions in Patients Submitted to Physical Therapy	N/A
Completed	`NCT01679301` - Evaluation of Sleep Mode Within the Respironics SimplyGo Portable Oxygen Concentrator	N/A
Completed	`NCT02345135` - Susceptibility to Infections in Ataxia Telangiectasia	N/A
Terminated	`NCT00966823` - Fetal Tracheal Balloon Study in Diaphragmatic Hernia	Phase 2
Completed	`NCT00139152` - Non-invasive Ways to Evaluate Lung Disease After Treatment With Xolair	Phase 4
Completed	`NCT00052052` - An Open-Label Study of the Safety and Efficacy of Subcutaneous Recombinant Interferon-Gamma 1b (IFN-Gamma 1b) in Patients With Idiopathic Pulmonary Fibrosis (IPF)	Phase 2
Completed	`NCT00013949` - Cardiovascular Vulnerability to Particulate Exposure	N/A
Recruiting	`NCT02965300` - The Value of VOCs Analysis in Exhaled Breath for Pulmonary Benign and Malignant Lesion Diagnosis	N/A
Enrolling by invitation	`NCT02946658` - Use of Autologous, Adult Adipose-Derived Stem/Stromal Cells In Chronic Lung Disorders	Phase 1/Phase 2
Recruiting	`NCT02913365` - Etiologies, Investigations and Outcomes of Patients Presenting With Hemoptysis	N/A
Completed	`NCT01735526` - Lung Diffusing Capacity for Nitric Oxide and Carbon Monoxide After Hematopoietic Stem-cell Transplantation	N/A
Completed	`NCT01952002` - Clinical Safety for the Inspiratory Muscle Training	N/A
Recruiting	`NCT01450644` - Evaluation of the Hospital2Home Palliative Care Service for Patients With Advanced Progressive Lung Disease	Phase 2
Completed	`NCT01215279` - AZD2423 Safety and Tolerability Study in Patients With Moderate and Severe Chronic Obstructive Pulmonary Disease(COPD)	Phase 2
Completed	`NCT01153321` - Investigation of the Effect of Oral Treatment With 100 mg AZD2423 in Subjects With Mild Chronic Obstructive Pulmonary Disease (COPD)	Phase 2
Completed	`NCT00837681` - Pulmonary Complications of Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT02055222` - Clinical Outcomes and Molecular Phenotypes in Smokers With Parenchymal Lung Disease
Completed	`NCT01222442` - To Evaluate the Effect of AZD3199 on the Electrical Activity in the Heart	Phase 1
Recruiting	`NCT02723474` - A Single-Centre Pilot Study Exploring the Utility of Magnetic Resonance Imaging in Patients With Chronic Lung Disease	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.